BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 35383859)

  • 1. Identification of the most common BRCA alterations through analysis of germline mutation databases: Is droplet digital PCR an additional strategy for the assessment of such alterations in breast and ovarian cancer families?
    Lavoro A; Scalisi A; Candido S; Zanghì GN; Rizzo R; Gattuso G; Caruso G; Libra M; Falzone L
    Int J Oncol; 2022 May; 60(5):. PubMed ID: 35383859
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Performance of multiplicom's BRCA MASTR Dx kit on the detection of BRCA1 and BRCA2 mutations in fresh frozen ovarian and breast tumor samples.
    Badoer C; Garrec C; Goossens D; Ellison G; Mills J; Dzial M; El Housni H; Berwouts S; Concolino P; Guibert-Le Guevellou V; Delnatte C; Del Favero J; Capoluongo E; Bézieau S
    Oncotarget; 2016 Dec; 7(49):81357-81366. PubMed ID: 27793035
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Germline mutations in BRCA1 and BRCA2 among Brazilian women with ovarian cancer treated in the Public Health System.
    de Oliveira Ferreira C; Carneiro VCG; Araujo Mariz C
    BMC Cancer; 2024 Apr; 24(1):499. PubMed ID: 38641594
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Tumor Suppressor BRCA1/2, Cancer Susceptibility and Genome Instability in Gynecological and Mammary Cancers.
    Oubaddou Y; Ben Ali F; Oubaqui FE; Qmichou Z; Bakri Y; Ameziane El Hassani R
    Asian Pac J Cancer Prev; 2023 Sep; 24(9):3139-3153. PubMed ID: 37774066
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Breast cancer in West Africa: molecular analysis of BRCA genes in early-onset breast cancer patients in Burkina Faso.
    Biancolella M; Ouédraogo NLM; Zongo N; Zohoncon TM; Testa B; Rizzacasa B; Latini A; Conte C; Compaore TR; Ouedraogo CMR; Traore SS; Simpore J; Novelli G
    Hum Genomics; 2021 Oct; 15(1):65. PubMed ID: 34717758
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Novel Germline Mutation of BRCA1 and Integrated Analysis With Somatic Mutation in a Chinese Multi-Cancer Family.
    Yang X; Shang L; Yang L; Sun L; Tuo X; Ma S; Zhao L; Li X; Yang W
    Oncologist; 2024 Jun; 29(6):e837-e842. PubMed ID: 38159086
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preliminary insights on the mutational spectrum of BRCA1 and BRCA2 genes in Pakhtun ethnicity breast cancer patients from Khyber Pakhtunkhwa (KP), Pakistan.
    Ahmad H; Ali A; Ali R; Khalil AT; Khan I; Khan MM; Alorini M
    Neoplasia; 2024 May; 51():100989. PubMed ID: 38537553
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The biological effects and clinical implications of BRCA mutations: where do we go from here?
    Stoppa-Lyonnet D
    Eur J Hum Genet; 2016 Sep; 24 Suppl 1(Suppl 1):S3-9. PubMed ID: 27514841
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Germline copy number variations in BRCA1/2 negative families: Role in the molecular etiology of hereditary breast cancer in Tunisia.
    Boujemaa M; Hamdi Y; Mejri N; Romdhane L; Ghedira K; Bouaziz H; El Benna H; Labidi S; Dallali H; Jaidane O; Ben Nasr S; Haddaoui A; Rahal K; Abdelhak S; Boussen H; Boubaker MS
    PLoS One; 2021; 16(1):e0245362. PubMed ID: 33503040
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Chao A; Lin YH; Yang LY; Wu RC; Chang WY; Chang PY; Chang SC; Lin CY; Huang HJ; Lin CT; Chou HH; Huang KG; Kuo WL; Chang TC; Lai CH
    J Gynecol Oncol; 2020 May; 31(3):e24. PubMed ID: 31912679
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hereditary breast and ovarian cancer: from genes to molecular targeted therapies.
    Ponti G; De Angelis C; Ponti R; Pongetti L; Losi L; Sticchi A; Tomasi A; Ozben T
    Crit Rev Clin Lab Sci; 2023 Dec; 60(8):640-650. PubMed ID: 37455374
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of inherited mutations for breast and ovarian cancer using genomic capture and massively parallel sequencing.
    Walsh T; Lee MK; Casadei S; Thornton AM; Stray SM; Pennil C; Nord AS; Mandell JB; Swisher EM; King MC
    Proc Natl Acad Sci U S A; 2010 Jul; 107(28):12629-33. PubMed ID: 20616022
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of RAD51D in ovarian cancer patients and families with a history of ovarian or breast cancer.
    Thompson ER; Rowley SM; Sawyer S; kConfab ; Eccles DM; Trainer AH; Mitchell G; James PA; Campbell IG
    PLoS One; 2013; 8(1):e54772. PubMed ID: 23372765
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development and validation of a variant detection workflow for BRCA1 and BRCA2 genes and its clinical application based on the Ion Torrent technology.
    Buzolin AL; Moreira CM; Sacramento PR; Oku AY; Fornari ARDS; Antonio DSM; Quaio CRDAC; Baratela WR; Mitne-Neto M
    Hum Genomics; 2017 Jun; 11(1):14. PubMed ID: 28651617
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characteristics of germline DNA damage response gene mutations in ovarian cancer in Southwest China.
    Fu K; Li Q; Wang J; Zhang M; Yan X; Li K; Song L; Zhong L; Ma Y; Chen J; Zeng J; Wang D; Shao D; Zhu S; Yin R
    Sci Rep; 2024 Mar; 14(1):6702. PubMed ID: 38509102
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Germline BRCA2 pathogenic variants in pediatric ganglioglioma: Case report and review of the literature.
    Gupta A; Lechpammer M; Brossier NM
    Childs Nerv Syst; 2024 May; 40(5):1609-1612. PubMed ID: 38168858
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Establishing the origin of metastatic deposits in the setting of multiple primary malignancies: the role of massively parallel sequencing.
    De Mattos-Arruda L; Bidard FC; Won HH; Cortes J; Ng CK; Peg V; Nuciforo P; Jungbluth AA; Weigelt B; Berger MF; Seoane J; Reis-Filho JS
    Mol Oncol; 2014 Feb; 8(1):150-8. PubMed ID: 24220311
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BRCA1/2 testing for genetic susceptibility to cancer after 25 years: A scoping review and a primer on ethical implications.
    Petrova D; Cruz M; Sánchez MJ
    Breast; 2022 Feb; 61():66-76. PubMed ID: 34920368
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of germline alterations of the mad homology 2 domain of SMAD3 and SMAD4 from the Ontario site of the breast cancer family registry (CFR).
    Tram E; Ibrahim-Zada I; Briollais L; Knight JA; Andrulis IL; Ozcelik H
    Breast Cancer Res; 2011 Aug; 13(4):R77. PubMed ID: 21835029
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Molecular Detection of Germline Mutations in the
    Grigore LG; Radoi VE; Serban A; Mihai AD; Stoica I
    Curr Issues Mol Biol; 2024 May; 46(5):4630-4645. PubMed ID: 38785549
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.